Pharmaceuticals

NOVARTIS AG

Salesforce

Conference Minutes

INFA

OpenAI

DXYZ

GOOG

GOOGL

GGLS

GGLL

ARR-C

<p>The following are the minutes of the FY26Q3 earnings call for <span class="security-tag" type="security-tag" counter_id="ST/US/CRM" name="Salesforce" trend="">$Salesforce(CRM.US)</span> compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article &#34;Salesforce: Is the AI Agent 'Delayed', and Has the SaaS Leader Become a Value Stock?&#34; 1. Review of Core Financial Information Guidance: The company is still expected to reaccelerate revenue growth within the next 12 to 18 months. Net new AOV growth: Net new AOV growth in the second half of FY26 is expected to exceed AOV growth in the second half...</p>

Informatica

Destiny Tech100

Haleon

Alphabet - C

Alphabet

IRSA Inversiones

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Armour Residential Reit

Gartner

Hasbro

ING Groep

ARMOUR RESIDENTIAL REIT INC 7.00% CUM RED PFD STK SER C

Salesforce (Minutes): The foundation of technology and sales has been laid, looking forward to the harvest period

Zacks Research downgrades Novartis Q1 2027 EPS estimate

Novartis to Acquire Excellergy for Up to $2 Billion

Morgan Stanley raises Novartis target price to $170 and maintains an overweight rating

FactSet Raises Novartis Target Price to $164.26

Alibaba Health and Novartis Announce Chronic Spontaneous Urticaria Digital Chronic Disease Collaboration

Novartis Invests in SNV4818 to Redefine Breast Cancer Treatment Market Position

Novartis to present remibrutinib phase 3 aggregate data for chronic spontaneous urticaria at AAD annual meeting

China's commerce minister meets US pharma executives to discuss business environment improvement

Barclays reiterates hold rating for Novartis

Novartis and Collegium Announce Acquisition Agreements to Enhance Therapeutic Pipeline

Novartis Acquires Synnovation Therapeutics for $3 Billion

Novartis Finances Acquisition of Avidity Biosciences with Debt

Novartis to Repurchase up to 10% of Its Registered Shares Over Next Three Years

Novartis Receives FDA Approval for Pyogenic Hidradenitis Treatment

FDA Approves Novartis' Cosentyx for Specific Pediatric Patients with Moderate to Severe Acne Conglobata

Novartis upgraded to Buy with a target price of $180

US President Trump claims tariffs affect Novartis

Novartis Receives Positive Opinion from EMA for Rimegepant

Novartis Plans to Establish a Radioligand Therapy Production Base in Texas

Ethos Urges Novartis Shareholders to Reject CEO's High Compensation

Visionary

Sky Quarry

TMD Energy

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Semilux

Cocrystal Pharma

Sidus Space

Swarmer

Franklin Covey

Biodexa Pharmaceuticals

Earning Release Date

财报预告

FY2026 Q1 Earning Release 2026.04.28 (EST)

Novartis (NVS.US) 2024 Third Quarter Earnings Conference Call

Eli Lilly

ROCHE HOLDINGS AG

Roche

AstraZeneca

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Otsuka Pharmaceutical

Daiichi Sankyo

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

NOVARTIS AG(NVS.US)

NOVARTIS AG Stock Performance Chart

Trending